Effect of anti-seizure drugs on serum S100B in patients with focal seizure: a randomized controlled trial

Maiti, Rituparna; Mishra, Biswa Ranjan; Jena, Monalisa; Mishra, Archana; Nath, Santanu; Srinivasan, Anand

doi:10.1007/s00415-018-9026-1

Cited by 15 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several investigators have demonstrated elevated brain injury marker levels in epilepsy, but there is not much data on levels in adults with new-onset seizures. Our results are well in line with previous studies of elevated S100B levels in epilepsy [25][26][27], which indicate that this marker should be investigated further for biomarker potential early in the disease course and perhaps as a marker of seizure burden. Pathophysiologically, increased levels of S100B could result from disruption of the blood brain barrier [14,28,29].…”

Section: Discussionsupporting

confidence: 91%

Brain injury markers in new-onset seizures in adults: A pilot study

Eriksson

Banote

Larsson

et al. 2021

Seizure

View full text Add to dashboard Cite

Background: Biochemical markers of brain pathology could potentially contribute to diagnosis and prediction in epilepsy. We describe levels of five brain injury markers in adults with new-onset seizures, and assess group differences in patients with a single seizure, epilepsy, and poststroke epilepsy. Methods: In this prospective observational study, adults with new-onset seizures were recruited at Sahlgrenska University Hospital, Sweden, and concentrations of glial fibrillary acidic protein (GFAP), neurofilament light (NfL), microtubule-associated protein tau (tau), S100 calcium-binding protein (S100B), and neuron-specific enolase (NSE) were measured. Participants were categorized as epilepsy, poststroke epilepsy (PSE), or single seizure (no additional seizures). Patients were followed until a diagnosis of epilepsy or PSE, or for at least two years in single seizure cases. Results: The cohort included 23 (37%) individuals with a single seizure, 24 (39%) with epilepsy, and 15 (24%) with PSE. The concentrations of S100B were higher in patients with epilepsy and PSE than in single seizures (p = 0.0023 and p = 0.0162, respectively). The concentrations of NfL were higher in patients with PSE than in single seizures (p=0.0027). After age-normalization, levels of S100B were higher in patients with epilepsy and levels of NfL were higher in patients with PSE (p = 0.0021 and p = 0.0180). Conclusion: Levels of S100B and NfL were higher in patients with epilepsy or PSE than patients with single seizures. Further studies are needed to investigate the biomarker potential of brain injury markers as predictors of epilepsy course or indicators of epileptogenesis.

show abstract

Section: Discussionsupporting

confidence: 91%

Brain injury markers in new-onset seizures in adults: A pilot study

Eriksson

Banote

Larsson

et al. 2021

Seizure

View full text Add to dashboard Cite

show abstract

“…Recent meta-analysis studies, that systematically analyzed all the available data about the presence of S100B in the serum of epileptic patients, confirmed the significant increase of S100B, indicating that epileptic seizures induce a boost and consequent release of brain biomarkers in the blood from the brain (Liang et al, 2019;Simani et al, 2020). Moreover, in patients with focal seizure, the anti-seizure drug carbamazepine was shown to significantly decrease serum S100B level (Maiti et al, 2018), and in a further study performed in patients with refractory epilepsy, serum S100B levels were found significantly to decrease after administration of the anti-epileptic levetiracetam (Dyck et al, 2002).…”

Section: Epilepsymentioning

confidence: 88%

Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders

Michetti

Sante

Clementi³

et al. 2021

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…8 Elevated S100Blevels have been demonstrated in adults and children with temporal lobe epilepsy (TLE). [13][14][15] In one study, S100B was higher in female TLE patients than males, hinting at possible interactions between S100B and sex hormones. 16 Some findings have been inconsistent, reporting no significant differences between epilepsy and control groups 17,18 or even a decrease in serum S100B levels in epilepsy.…”

Section: S100 Calcium-binding Protein B (S100b)mentioning

confidence: 99%

“…However, in the acute phase of stroke low levels of S100B have been associated with an increased risk of later poststroke epilepsy 8 . Elevated S100B‐levels have been demonstrated in adults and children with temporal lobe epilepsy (TLE) 13–15 . In one study, S100B was higher in female TLE patients than males, hinting at possible interactions between S100B and sex hormones 16 .…”

Section: Blood Biomarkers Of Epilepsymentioning

confidence: 99%

Blood biomarkers in epilepsy

Banote

Akel

Zelano

2022

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Robust and accessible biomarkers are greatly needed in epilepsy. Diagnostic and prognostic precision in the clinic needs to improve, and there is a need for objective quantification of seizure burden. In recent years, there have been advances in the development of accessible and cost‐effective blood‐based biomarkers in neurology, and these are increasingly studied in epilepsy. However, the field is in its infancy and specificity and sensitivity for most biomarkers in most clinical situations are not known. This review describes advancements regarding human blood biomarkers in epilepsy. Examples of biochemical markers that have been shown to have higher blood concentrations in study subjects with epilepsy include brain proteins like S100B or neuronal specific enolase, and neuroinflammatory proteins like interleukins, and tumor necrosis factor‐alpha. Some of the blood biomarkers also seem to reflect seizure duration or frequency, and levels decrease in response to treatment with antiseizure medication. For most biomarkers, the literature contains seemingly conflicting results. This is to be expected in an emerging field and could reflect different study populations, sampling or analysis techniques, and epilepsy classification. More studies are needed with emphasis put on the classification of epilepsy and seizure types. More standardized reporting could perhaps decrease result heterogeneity and increase the potential for data sharing and subgroup analyses.

show abstract

Effect of anti-seizure drugs on serum S100B in patients with focal seizure: a randomized controlled trial

Abstract: Serum S100B increases in the patients with focal seizure and therapy with carbamazepine can decrease serum S100B level significantly over oxcarbazepine. Serum S100B can be used as a prognostic biomarker in a focal seizure.

Cited by 15 publications

References 34 publications

Brain injury markers in new-onset seizures in adults: A pilot study

Brain injury markers in new-onset seizures in adults: A pilot study

Growing role of S100B protein as a putative therapeutic target for neurological- and nonneurological-disorders

Blood biomarkers in epilepsy

Contact Info

Product

Resources

About